Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;8(15):975.
doi: 10.21037/atm.2020.03.164.

Translating KEYNOTE-048 into practice recommendations for head and neck cancer

Petr Szturz  1 , Jan B Vermorken  2   3
Affiliations
Editorial

Translating KEYNOTE-048 into practice recommendations for head and neck cancer

Petr Szturz et al. Ann Transl Med. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.164). PS has had in the last three years consulting/advisory relationships with Merck-Serono, Servier, and BMS and has received honoraria from Merck-Serono. JBV has had in the last three years consulting/advisory relationships with Immunomedics, Innate Pharma, Merck-Serono, Merck Sharp & Dome Corp, PCI Biotech, Synthon Biopharmaceuticals, Debiopharm, Cue Biopharma, and WntResearch and has received honoraria from Merck-Serono, MSD, and BMS.

Figures

Figure 1
Figure 1
Systemic treatment algorithm for recurrent and/or metastatic squamous cell carcinoma of the head and neck outside clinical trials. *other drugs that can be suggested include methotrexate, afatinib, or palbociclib with cetuximab as summarized in (4). †pembrolizumab can be used in patients who progressed within 3–6 months after completing platinum-based chemoradiotherapy especially if TPS ≥50%. PFE, platinum/5-fluorouracil/cetuximab regimen according to the EXTREME trial; TPEx, docetaxel/platinum/cetuximab regimen; PD-L1, ligand for programmed cell death protein-1; esp., especially; TPS, tumour proportion score; 5-FU, 5-fluorouracil.
See this image and copyright information in PMC

Comment on

References

    1. Ferris RL, Blumenschein G, Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67. 10.1056/NEJMoa1602252 - DOI - PMC - PubMed
    1. Burtness B, Harrington KJ, Greil R, at al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-28. 10.1016/S0140-6736(19)32591-7 - DOI - PubMed
    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27. 10.1056/NEJMoa0802656 - DOI - PubMed
    1. Szturz P, Vermorken JB. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncol 2020;101:104492. 10.1016/j.oraloncology.2019.104492 - DOI - PubMed
    1. Vermorken JB, Peyrade F, Krauss J, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol 2014;25:682-8. 10.1093/annonc/mdu003 - DOI - PMC - PubMed